Post by BioThrust

🚀 𝗖𝗚𝗧 𝗖𝗼𝘀𝘁𝘀 𝗪𝗼𝗻’𝘁 𝗗𝗿𝗼𝗽 𝗪𝗶𝘁𝗵𝗼𝘂𝘁 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 Cost reduction in cell therapy isn’t just a scale problem, it’s a process problem. Scaling up inefficient systems might reduce batch count. Sure, it looks like progress. 𝗕𝘂𝘁 𝗹𝗲𝘁’𝘀 𝗯𝗲 𝗵𝗼𝗻𝗲𝘀𝘁 👇 👉 Bigger ≠ Better if your process isn’t optimized. What scales mostly is your media cost… The real breakthrough in CGT COGS will come from something else entirely: 🔥 Process intensification at scale - Higher cell densities - Exponentially increased yield - Maintained (or improved) cell quality - Real impact on viable cells per run At BioThrust, we’re focused on exactly that: Building novel bioreactors that don’t just scale… but scale efficiently! The secret trick? Unlocking gas transfer bottlenecks that limit virtually every other bioreactor technology out there. 📊 In the carousel: A closer look at iPSC expansion and how different systems compare in cost per billion cells. The cell numbers are taken from our internal runs and published literature. The cost estimations are purely for reference and based on internal calculations - let us know if you have data to compare!